Clinical Trial Finder

Inclusion Criteria:

• - Age ≥ 18 years.

• - Diagnosis of brain tumor requiring cranial radiation treatment NOTE: Patient may be enrolled during or up to 3 years after completion of cranial radiation administered for treatment of primary or metastatic intracranial tumor.

• - Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2, AND Karnofsky performance status (KPS) of ≥ 70.

• - Expected survival ≥ 6 months in the opinion of treatment team.

• - Willing and able to adhere with the protocol for the duration of the study including undergoing treatment, and attending scheduled visits, and examinations.

• - The following laboratory values obtained ≤ 30 days prior to registration: - Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 x ULN [≤ 5 x upper limit normal (ULN) for patients with baseline liver disease] - Negative pregnancy test ≤ 8 days prior to registration for persons of childbearing potential only.

• - Ability to complete cognitive assessments and questionnaires by themselves or with assistance.

Exclusion Criteria:

• - Uncontrolled and/or intercurrent illness or other condition which limits safety of or compliance with study proceedings.

• - Pregnant or nursing, imprisoned, or lacking capacity for understanding.

• - Unable to swallow tablets or at risk for impaired absorption of oral medication.

• - Currently taking the study agent (i.e., metformin), and cannot safely discontinue if randomized to the control group (Group B) - Known hypersensitivity or allergy to metformin.

• - Current use of resveratrol, CoQ10 (coenzyme Q10), coconut oil/other medium chain triglyceride-containing (e.g., Axona) supplements, or curcumin and unwilling to discontinue prior to registration and remain off these agents for study duration.

• - Unable to read and speak English.

Note: English doses not to need to be primary language

PRIMARY OBJECTIVE:

• I. Determine the feasibility of completing serial remote cognitive, activity/sleep, and self-report assessments in clinical trial participants who have previously received cranial radiation.

SECONDARY OBJECTIVES:

• I. Assess the acceptance or satisfaction of patients with the remote monitoring in this trial and how these may differ between those who receive metformin versus (vs.#46;) not.

• II. Evaluate compliance and feasibility in terms of the adherence to study drug in those randomized to receive metformin.

• III. Assess and compare neurocognitive function scores and the impact of receiving metformin + health promotion with wearable device vs.#46; wearable device only.

• IV. Assess the safety and tolerability of metformin in patients who have previously received cranial radiation.

EXPLORATORY OBJECTIVES:

• I. Investigate the relationship of metformin and other health outcomes such as activity and sleep data and how these compare to the results for patients who are randomized to the control group, who do not receive metformin.

• II. Explore potential differences in these compliance and satisfaction measures and how they may correspond to health disparities and social determinants of health.

OUTLINE: Patients are randomized to 1 of 2 groups. GROUP A: Patients receive metformin orally (PO) twice day (BID) for 12 months. Treatment repeats every 28 days for up to 12 months in the absence of disease progression or unacceptable toxicity. Patients also wear a wearable device to monitor health and undergo neurocognitive test throughout the study. GROUP B: Patients receive standard of care (SOC) treatment for 12 months. Patients also wear a wearable device to monitor health and undergo neurocognitive test throughout the study. Upon completion of study treatment, patients are followed up at 30 days then every 3 months for up to 2 years.

Arms

Experimental: Group A (metformin)

Patients receive metformin PO BID for 12 months. Treatment repeats every 28 days for up to 12 months in the absence of disease progression or unacceptable toxicity. Patients also wear a wearable device to monitor health and undergo neurocognitive test throughout the study.

Active Comparator: Group B (usual care)

Patients receive SOC treatment for 12 months. Patients also wear a wearable device to monitor health and undergo neurocognitive test throughout the study.

Interventions

Other: - Best Practice

Receive SOC

Other: - Medical Device Usage and Evaluation

Wear wearable device

Drug: - Metformin

Given PO

Other: - Neurocognitive Assessment

Undergo neurocognitive test

Other: - Questionnaire Administration

Ancillary studies